Eloxx Pharmaceuticals (ELOX) and Its Competitors Financial Review

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Eloxx Pharmaceuticals to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends.

Profitability

This table compares Eloxx Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,319.38%	-223.57%	-16.98%

Earnings & Valuation

This table compares Eloxx Pharmaceuticals and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-11.16
Eloxx Pharmaceuticals Competitors	$3.57 billion	$3.15 billion	546.16

Eloxx Pharmaceuticals’ rivals have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Eloxx Pharmaceuticals and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	3	1	2.80
Eloxx Pharmaceuticals Competitors	7597	13659	25475	1001	2.42

Eloxx Pharmaceuticals presently has a consensus target price of $38.33, indicating a potential upside of 123.00%. As a group, “Pharmaceuticals” companies have a potential upside of 26.56%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Eloxx Pharmaceuticals is more favorable than its rivals.

Risk and Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, suggesting that its stock price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ rivals have a beta of -3.17, suggesting that their average stock price is 417% less volatile than the S&P 500.

Summary

Eloxx Pharmaceuticals beats its rivals on 8 of the 13 factors compared.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.